NCT00826878 2012-06-28An Open-Label Study of QD Oral Administration of Tivozanib (AV-951) in Subjects With Non-Small Cell Lung Cancer (NSCLC)AVEO Pharmaceuticals, Inc.Phase 1 Completed17 enrolled